Clinical Unmet Need

As of 2017, an approximate population of 14 million people in the US were diagnosed with Age-related Macular Degeneration (AMD) [1], with an estimated total of 196 million people being affected worldwide by 2020, increasing to 288 million people by 2040 [2]. Additional studies have shown that there is a strong possibility that AMD is underdiagnosed by up to 25% in primary care, with these cases often being in the very early stage of AMD [3].

 

However, due to the aggressive nature of Wet AMD, cases are diagnosed more rapidly. Wet AMD also represents approximately 10% of all cases of AMD [4]. This amounts to a total of 1.4 million people in the US as of 2017, with an estimated increase to 2 million people in the US by 2020. Globally Wet AMD will affect an estimated 19.6 million people by 2020 with a projected growth to 28.8 million people by 2040.

References:

1. Age-Related Macular Degeneration: Facts & Figures | Bright Focus Foundation - [online] Available at: www.brightfocus.org/macular/article/age-related-macular-facts-figures

2. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors | U.S. National Institutes of Health's National Library of Medicine - [online] Available at: www.ncbi.nlm.nih.gov/pmc/articles/PMC5178091/

3. Study: Is AMD underdiagnosed in primary care? | American Optometric Association - [online] Available at: www.aoa.org/news/clinical-eye-care/prevalence-of-undiagnosed-amd

4. Age-Related Macular Degeneration: Facts & Figures | Bright Focus Foundation - [online] Available at: www.brightfocus.org/macular/article/age-related-macular-facts-figures

 
Optigo-logo_Hor_wo-tagline-website.png

© 2019 Optigo Biotherapeutics Inc. All rights reserved.